Clinical Evaluation of Acetaminophen-Galgeuntang Interaction Based on Population Approaches.
Galgeuntang
acetaminophen
drug interaction
population pharmacokinetics
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
04 Dec 2020
04 Dec 2020
Historique:
received:
30
10
2020
revised:
28
11
2020
accepted:
01
12
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
Galgeuntang (GGT), a traditional herbal medicine, is widely co-administered with acetaminophen (AAP) for treatment of the common cold, but this combination has not been the subject of investigation. Therefore, we investigated the herb-drug interaction between GGT and AAP by population pharmacokinetics (PKs) modeling and simulation studies. To quantify PK parameters and identify drug interactions, an open label, three-treatment, three-period, one-sequence (AAP alone, GGT alone, and AAP and GGT in combination) clinical trial involving 12 male healthy volunteers was conducted. Ephedrine (EPD), the only GGT component detected, was identified using a one-compartment model. The PKs of AAP were described well by a one-compartment model and exhibited two-phase absorption (rapid followed by slow) and first-order elimination. The model showed that EPD significantly influenced the PKs of AAP. The simulation results showed that at an AAP dose of 1000 mg × 4 times daily, the area under the concentration versus time curve of AAP increased by 16.4% in the presence of GGT compared to AAP only. In conclusion, the PKs of AAP were affected by co-administration of GGT. Therefore, when AAP is combined with GGT, adverse effects related to overdose of AAP could be induced possibly.
Identifiants
pubmed: 33291732
pii: pharmaceutics12121182
doi: 10.3390/pharmaceutics12121182
pmc: PMC7761965
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Chungnam National University (CNU) and by Institute of Information & communications Technology Planning & Evaluation (IITP)
ID : No.2020-0-01441
Organisme : the Korea Healthcare technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea
ID : HI15C0006
Références
J Ethnopharmacol. 2011 Apr 12;134(3):614-23
pubmed: 21232589
Xenobiotica. 2017 Nov 21;:1-26
pubmed: 29160125
Pharmacology. 2010;86(5-6):287-92
pubmed: 21042038
Planta Med. 2014 May;80(7):561-7
pubmed: 24710899
J Hepatol. 2017 Dec;67(6):1324-1331
pubmed: 28734939
Int J Environ Res Public Health. 2015 Dec 25;13(1):84
pubmed: 26712778
J Pharm Pharmacol. 2012 Oct;64(10):1445-51
pubmed: 22943175
Arch Pharm Res. 2007 Oct;30(10):1309-17
pubmed: 18038910
Clin Pharmacol Ther. 1978 Oct;24(4):420-31
pubmed: 688732
J Pharm Sci. 1991 Sep;80(9):855-60
pubmed: 1800709
Biopharm Drug Dispos. 2011 Nov;32(8):458-70
pubmed: 22024968
Medicine (Baltimore). 2018 Jun;97(25):e11196
pubmed: 29924041
Br J Clin Pharmacol. 1975 Dec;2(6):509-13
pubmed: 9953
Pharmacogenet Genomics. 2015 Aug;25(8):416-26
pubmed: 26049587
Br J Pharmacol. 1973 Feb;47(2):415-21
pubmed: 4722050
Br J Clin Pharmacol. 2015 Sep;80(3):381-8
pubmed: 25784216
Life Sci. 2000 Nov 3;67(24):2997-3006
pubmed: 11133012
Expert Opin Drug Saf. 2005 Mar;4(2):355-78
pubmed: 15794726
Arch Pharm Res. 2010 Feb;33(2):243-6
pubmed: 20195825
Crit Rev Toxicol. 2001 Jan;31(1):55-138
pubmed: 11215692
Food Chem Toxicol. 2013 Jan;51:343-9
pubmed: 23104244
Pharmazie. 2014 May;69(5):367-70
pubmed: 24855829